Tuesday, 16 Oct 2018

You are here

Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA

Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides. A single center cross -sectional observational study was designed to conduct deeper analysis of Cardiovascular Risk Factors (CVRF) in patients with PsA, PSO without arthritis and SpA without PSO (THU 0297). Authors aimed at identifying association between CVRF and presence of either arthritis or skin disease. 

In this study of 300 patients with PSA, PSO and SpA, 29.7% reported Hypertension (HTN), 11.7% Type 2 Diabetes Melitus(T2DM) and 29% Dyslipidemia (DL). In comparison with general population entire study group comprised 100 patients with SpA without PSO (33.3%), 100 patients with PsA (33.3%) and PSO without articular disease (13%) exhibited higher prevalence of HTN and DL (p <0.005). Inside the study group though, where was no significant difference in prevalence of CVEF between all three studied diagnoses ( Fig below).

HTN was significantly associated with AINEs intake (OR 1.79; p<0.005) and disease duration (OR 1.02). No association with gender or age was found in this study.  neither PSA/SpA nor PSO were associated with development of T2DM or dyslipidemia. 

Study concluded that although prevalence of CVRF was higher in the study group comparing to general population, no significant difference was found in regards to skin vs articular disease. authors hint at association between NSAIDs use and HTN which would require further studies to specify.

image2.jpeg

 

image3.jpeg

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Apremilast Succeeds in Scalp Psoriasis

Celgene has announced results from the phase 3 STYLE study, showing apremilast yielding significant improvement in moderate-to-severe scalp psoriasis. STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive apremilast 30 mg twice daily or placebo for the first 16 weeks.

Does Gender Make a Difference in Axial Spondyloarthritis

Males and females can both be affected by axial spondyloarthritis (axSpA). A recent study shows that while there are some differences and similarities, HLA-B27 and imaging are still pivotal elements for diagnosis of axSpA in both genders.

Complementary Therapies in Psoriasis

A systematic review in Archives of Dermatology suggests that among complementary and alternative medicine (CAM) therapies, the most effective are indigo naturalis, curcumin, dietary modification, meditation, and acupuncture.

It is estimated that  nearly half of patients with psoriasis report they use CAM, although their benefits are unclear in psoriasis.

Biologic Therapies Improve Work Outcomes in Spondyloarthritis

A study from the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBR-AS) shows that biologic use significantly improves work productivity and overall activity impairment.

 

The BSRBR-AS registry analyzed 577 participants who were employed;  28% were started on biological therapy .

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.